EP1674104A1 — Uridine derivatives as antiviral drugs against a flaviviridae, especially HCV
Assigned to Centre National de la Recherche Scientifique CNRS · Expires 2006-06-28 · 20y expired
What this patent protects
The invention relates to the use of an uridine derivative of formula (I): wherein R 1 represents monohalogenated alkynyl or dihalogenated alkenyl; R 2 is chosen from among hydrogen, hydroxyl, -O-alkyl, -O-CO-alkyl and halogen; R 3 is chosen from among hydrogen, …
USPTO Abstract
The invention relates to the use of an uridine derivative of formula (I): wherein R 1 represents monohalogenated alkynyl or dihalogenated alkenyl; R 2 is chosen from among hydrogen, hydroxyl, -O-alkyl, -O-CO-alkyl and halogen; R 3 is chosen from among hydrogen, hydroxyl, -O-alkyl, -O-CO-alkyl, halogen, -SH, -S-alkyl and N 3 ; and R 4 is chosen from among hydroxyl, -O-alkyl, -O-CO-alkyl, -O-phosphate, -O-diphosphate, -O-triphosphate and -O-phosphonate, as well as its possible tautomers, its possible pharmaceutically acceptable addition salts with an acid or a base, and its N-oxide forms, for the preparation of a drug having antiviral activity against a Flaviviridae.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.